Volume 115, Issue 1, Pages 19-27 (July 1998) Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis  Helen M. Cawley*, Stephen J. Meltzer‡, Virna M.G. de Benedetti*, Monica C. Hollstein§, Karl–Rudolf Muehlbauer§, Linda Liang*, William P. Bennett*, Rhonda F. Souza‡, Bruce D. Greenwald‡, John Cottrell∥, Audrey Salabes∥, Helmut Bartsch§, Glenwood E. Trivers*  Gastroenterology  Volume 115, Issue 1, Pages 19-27 (July 1998) DOI: 10.1016/S0016-5085(98)70360-9 Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 1 Detection of p53-Ab by a three-assay system (EIA, immunoblotting, and immunoprecipitation in patients with Barrett's esophagus and esophageal cancer. Specific absorbance is the difference between absorbance in wells with BSA control protein and those with human p53 protein in the EIA. Markers are molecular weight indicators; CM-1 is a rabbit anti-p53 specific serum used as the positive controls in all the assays. Normal human plasma (noncancer) was used as a negative control, and plasma samples were prepared before, during, or after diagnosis (Dx). HB, high background; p53, position of molecular weight 53 indicated by the marker. Of the 12 patients whose results are shown, the figure includes (left to right) results from the 1 patient with SCC who had antibodies before diagnosis (patient 39), 1 patient with Barrett's metaplasia but no diagnosis of cancer (patient 62), and 2 patients with ADC who also had antibodies before clinical diagnosis of cancer (patients 2 and 88). Gastroenterology 1998 115, 19-27DOI: (10.1016/S0016-5085(98)70360-9) Copyright © 1998 American Gastroenterological Association Terms and Conditions

Fig. 2 Representative results of (A) DGGE and (B) DNA sequencing showing alterations in tumor cell DNA from patients with SCC of the esophagus and 1 patient with Barrett's metaplasia. (A) DGGE wild-type banding patterns from patients 6 (p53-Ab− Barrett's metaplasia) and 7 (p53-Ab+ SCC), compared with the abnormal banding from patients 32 and 94 (p53-Ab+ SCC) in exon 5 and abnormal DGGE banding of patient 27 (p53-Ab− SCC) compared with wild-type patterns of SCC patients 32 and 39 in exon 7. (B) Wild-type sequences of SCC patients 7 and 28 as they appear, respectively, in exons 5 and 7, which serve as reference for the specific nucleotide changes in the respective mutations occurring in p53-Ab+ SCC patient 32 (ACT > AAT) in codon 166 and in p53-Ab− SCC patient 27 (GGA > GCA) in codon 249. Gastroenterology 1998 115, 19-27DOI: (10.1016/S0016-5085(98)70360-9) Copyright © 1998 American Gastroenterological Association Terms and Conditions